The University of Michigan’s Presidential Biosciences Initiative has issued its second-round Request for Applications to U-M faculty, seeking high-impact scientific research initiatives aimed at solving critical problems in the biosciences.
In a reflection of the changing landscape for academic drug discovery at the University of Michigan, the Center for the Discovery of New Medicines will now be known as Michigan Drug Discovery.
Along with the change in name, comes a shift in direction, scope and emphasis.
The first Michigan Life Sciences Fellows have arrived at the University of Michigan, where they are investigating important biological questions related to multiple sclerosis, triple-negative breast cancer, and how complex living architectures form.
University of Michigan faculty members have been named to the American Academy of Arts and Sciences for their significant contributions in scholarly and professional fields.
Among the 213 fellows and 36 foreign honorary members identified as "exceptional scholars, leaders, artists, and innovators" are:
The University of Michigan Center for the Discovery of New Medicines has awarded early-stage funding for seven new drug discovery projects by faculty from across U-M.
Postdoctoral researchers are the engines that drive a large proportion of academic life sciences research. They perform vital roles in the laboratories of senior scientists — including mentoring undergraduate and graduate students — while building the skills, expertise and insights to launch an independent research career.
The biological sciences today provide a "spectacularly fertile landscape for discovery," and University of Michigan researchers must work across disciplines to identify and pursue those emerging opportunities, according to President Mark Schlissel.
Members of the Biosciences Initiative Coordinating Committee are:
Roger D. Cone, Ph.D., will serve as the new Mary Sue Coleman Director of the University of Michigan Life Sciences Institute, effective Sept. 1. His appointment was approved Thursday by the Board of Regents.
Most cancer drugs today work by attacking tumor growth. Researchers at the Life Sciences Institute, however, are taking aim at a different piece of the cancer puzzle — preventing its ability to spread to new parts of the body, known as metastasis, which is the cause of most cancer deaths.
Researchers at the Life Sciences Institute and School of Public Health have discovered a new class of anti-biofilm compounds derived from marine micro-organisms that show promise against a drug-resistant bacterium commonly associated with hospital-acquired infections.
The Center for the Discovery of New Medicines has awarded funding for five new drug discovery projects by U-M faculty that address critical health areas including chronic kidney disease, ovarian cancer, breast cancer, toxoplasmosis and atherosclerosis.
An advisory committee has been appointed to launch the search for the university's next Mary Sue Coleman Director of the Life Sciences Institute. The university is now accepting nominations and applications for the position.
Dr. Stephen J. Weiss, a medical researcher who has focused his efforts on understanding the molecular mechanisms underlying the ways in which cancer cells invade tissues and metastasize, will become interim director of the university's Life Sciences Institute.
Lia Min works at the intersection of art and science, where her training as a neuroscientist informs her creative inquiry and her art expresses ideas and questions about the scientific enterprise.
The Life Sciences Institute will celebrate its 10th anniversary with a two-day biomedicine symposium featuring an impressive list of former University of Michigan researchers.